<DOC>
	<DOCNO>NCT00279162</DOCNO>
	<brief_summary>Patients receive either gel contain calcipotriene plus betamethasone gel active ingredient treatment scalp psoriasis 8 week . After time patient receive gel contain calcipotriene betamethasone 44 week . In addition , patient receive ointment contain calcipotriene plus betamethasone treatment psoriasis trunk limbs 52 week . The objective study short-term efficacy gel , short long-term safety gel ointment .</brief_summary>
	<brief_title>Efficacy Safety Calcipotriene/Betamethasone Gel/Ointment Psoriasis</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Betamethasone benzoate</mesh_term>
	<mesh_term>Betamethasone-17,21-dipropionate</mesh_term>
	<mesh_term>Betamethasone</mesh_term>
	<mesh_term>Betamethasone Valerate</mesh_term>
	<mesh_term>Betamethasone sodium phosphate</mesh_term>
	<mesh_term>Calcipotriene</mesh_term>
	<mesh_term>Calcitriol</mesh_term>
	<criteria>Psoriasis involve least 10 % scalp amenable topical treatment maximum 40g gel per week . A score investigator 's assessment clinical sign scalp psoriasis least 2 ( moderate severity ) one clinical sign ( redness , thickness scaliness ) , least 1 ( slight severity ) two clinical sign . An investigator 's global assessment moderate , severe severe scalp psoriasis . Psoriasis vulgaris trunk and/or limbs amenable topical treatment maximum 60g ointment per week . An investigator 's global assessment moderate , severe severe psoriasis trunk/limbs . Attending hospital outpatient clinic private practice dermatologist treatment psoriasis . Patients selfreport : ethnicity Hispanic Latino , race , ethnicity Hispanic Latino , race Black African American . Following receipt verbal write information trial , patient must provide sign date informed consent trialrelated activity carry . Females childbearing potential must negative result urine pregnancy test randomisation must agree use adequate method contraception study . Patients fulfil US requirements/law participation study . PUVA Grenz ray therapy within 4 week prior randomisation . UVB therapy within 2 week prior randomisation . Systemic treatment biological therapy ( market otherwise ) possible effect psoriasis ( e.g. , alefacept , efalizumab , etanercept , infliximab ) within 3 month prior randomisation . Systemic treatment biologicals possible effect psoriasis ( e.g. , corticosteroid , vitamin D analogue , retinoids , hydroxycarbamide , azathioprine , methotrexate , cyclosporine , immunosuppressant ) within 4 week prior randomisation . Any topical treatment scalp ( except medicate shampoos emollient ) within 2 week prior randomisation ( medicated shampoos/emollients allow doubleblind phase ) . Shampoos contain corticosteroid , e.g . Clobex® , allow within 2 week prior randomisation . Planned use topical treatment psoriasis trunk limb , besides study medication , study exception : • emollient • medication use treat psoriasis skin fold and/or genitals ( medication may use purpose apart Class 15 corticosteroid . Topical treatment face Class 15 corticosteroid within 2 week prior randomisation . Planned initiation , change , concomitant medication could affect psoriasis ( e.g. , beta blocker , antimalaria drug , lithium ) doubleblind phase study . Treatment nonmarketed drug substance ( i.e. , agent yet make available clinical use follow registration ) within 4 week prior randomisation . Planned use chemical treatment hair ( eg relaxer , 'perms ' , colouring ) doubleblind phase study . Current diagnosis erythrodermic , exfoliative pustular psoriasis . Patients follow condition also present psoriatic area scalp trunk/limbs : viral ( e.g . herpes varicella ) lesion skin , fungal bacterial skin infection , parasitic infection , skin manifestation relation tuberculosis syphilis , rosacea , acne rosacea , acne vulgaris , atrophic skin , stria atrophicae , fragility skin vein , ichthyosis , ulcer wound . Other inflammatory skin disease may confound evaluation psoriasis scalp trunk/limbs .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
</DOC>